Clinical Trial Update: A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of lucinactant for inhalation in preterm neonates with respiratory distress syndrome was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome Newborn

Drugs mentioned

• lucinactant for inhalation (lucinactant)

Snippet

Sponsor: Windtree Therapeutics | Conditions: Respiratory Distress Syndrome, Newborn | Phase 2 | Status: TERMINATED | Results posted: 2023-05-24